Clinical Trial Detail

NCT ID NCT02538510
Title Pembrolizumab and Vorinostat in Treating Patients With Recurrent Squamous Cell Head and Neck Cancer and Salivary Gland Cancer That Is Metastatic and/or Cannot Be Removed by Surgery
Recruitment Active, not recruiting
Gender both
Phase Phase Ib/II
Variant Requirements no
Sponsors University of Washington
Indications

salivary gland cancer

head and neck squamous cell carcinoma

nasal cavity squamous cell carcinoma

paranasal sinus cancer

nasopharynx carcinoma

Therapies

Pembrolizumab + Vorinostat

Age Groups: adult

No variant requirements are available.